Advertisement
Advertisement
U.S. markets open in 5 hours 30 minutes
Advertisement
Advertisement
Advertisement
Advertisement

VolitionRx Limited (VNRX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
2.03000.0000 (0.00%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.0300
Open2.1000
Bid0.0000 x 1000
Ask0.0000 x 900
Day's Range1.9800 - 2.1000
52 Week Range1.8500 - 4.1400
Volume165,167
Avg. Volume76,233
Market Cap115.399M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-0.5310
Earnings DateAug 09, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VNRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • VolitionRX Limited
    Analyst Report: Guardant Health, Inc.Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • PR Newswire

    Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Diagnostic Oncology CRO, LLC ("DXOCRO") to undertake development and clinical validation studies for its Nu.Q® product portfolio in the United States.

  • PR Newswire

    VolitionRx Awarded $1.5 Million in Non-Dilutive Funding

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.

  • Newsfile

    VolitionRx Limited to Present at Investor Summit Group's Q3 Virtual Conference

    Henderson, Nevada--(Newsfile Corp. - August 3, 2022) - VolitionRx Limited (NYSE American: VNRX) today announced that company executives Cameron Reynolds, CEO, and Scott Powell, Head of Investor Relations, will be attending the Q3 Virtual Investor Summit. During the presentation, VolitionRx Limited's Chief Executive Officer, Cameron Reynolds, will highlight the Company's transformational business strategy, disruptive technology, noteworthy collaborations and partnerships, and the broader going-fo

Advertisement
Advertisement